Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.58 |
| ▸ | PDE4A | P27815 | 11/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565419 | 0.90 | PDE4A (0.70) | ELANEPDE4AKCNH2 | |
| SCHEMBL8437043 | 0.90 | PDE4A (0.54) | ELANEPDE4AKCNH2PDE4BPDE4C | |
| SCHEMBL7185413 | 0.89 | PDE4A (0.65) | ELANEPDE4AKCNH2 | |
| SCHEMBL7185969 | 0.89 | PDE4A (0.62) | ELANEPDE4AKCNH2 | |
| SCHEMBL7192676 | 0.88 | ELANE (0.58) | ELANEPDE4AKCNH2 | |
| SCHEMBL8237731 | 0.88 | PDE4A (0.53) | ELANEPDE4AKCNH2PDE4BPDE4C | |
| SCHEMBL6395629 | 0.87 | ELANE (0.61) | ELANEPDE4AKCNH2PDE4BPDE4C | |
| SCHEMBL1565338 | 0.87 | KCNH2 (0.52) | ELANEPDE4AKCNH2PDE4BPDE4C | |
| SCHEMBL7176953 | 0.87 | KCNH2 (0.54) | ELANEPDE4AKCNH2 | |
| SCHEMBL14347488 | 0.86 | KCNH2 (0.65) | PDE4AKCNH2PDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312334-B2 | Method of preparing inhibitors phosphodiesterase-4 | MERCK & CO. INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | PDE4B, PDE4A, PDE5A | ELANE 2243/4885PDE4A 2/4885KCNH2 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.